More importantly, well-known cancer pathways, such as TP53, NF-κB, and TGF-β pathways, are closely linked to the BCL2 family [12–20], which implies that these pathways could be potential targets for combination treatment with apoptosis modulating agents. The gene discussed is TGFB1; the disease is cancer.